MannKind Corporation is a specialty biopharmaceutical company focused on inhaled insulin (Afrezza) and inhaled therapeutics. The company has a decades-long history of dilutive financing, including massive loans from founder Alfred Mann and subsequent equity raises. MannKind is a textbook case of biotech serial dilution.
The DilutionWatch score for MNKD updates automatically as new SEC filings appear — typically within 60 seconds of EDGAR publication. View the live MNKD score →
Biotech companies face inherent dilution risk: drug development timelines are long, FDA approval is uncertain, and even successful drugs take years to generate sufficient commercial revenue. MannKind's Afrezza took over 20 years and billions of dollars to develop, funded largely through equity raises and dilutive debt.
DilutionWatch monitors the following filing types for MNKD and alerts you within minutes of new activity:
DilutionWatch scores range from 0 (minimal risk) to 100 (critical risk). Scores above 50 warrant close monitoring. A score of 75+ means multiple active dilution mechanisms are present simultaneously. Scores update with every new SEC filing.
Understanding MNKD's dilution risk requires understanding the broader sector it operates in. Dilution patterns vary significantly by sector — capital intensity, access to debt markets, and typical financing structures all affect how companies raise capital and how dilutive those raises are.
Track MNKD on DilutionWatch to see how it compares to peers in the Biotech / Pharmaceuticals sector on each dilution risk dimension.
MannKind has been publicly traded since 2004 and has issued shares consistently throughout that period. The company's development of Afrezza took two decades and required enormous capital, most of which was raised by diluting shareholders or through loans from founder Alfred Mann (which were later converted or refinanced).
Yes — MannKind commercially markets Afrezza (inhaled insulin) and has partnerships for other inhaled therapeutics. Revenue has been growing, but the company continues to invest in new drug candidates that require capital beyond what current products generate.
MNKD is frequently cited in educational contexts as an example of long-term biotech dilution. The combination of a capital-intensive development program, a prolonged commercialization timeline, and multiple dilutive financing rounds makes it a useful case study for investors learning about biotech dilution risk.
DilutionWatch monitors MNKD and 10,000+ other tickers with 60-second EDGAR polling. Add MNKD to your watchlist and get alerted the moment a dilution filing appears.
Set Up MNKD Alert Free →All MNKD SEC filings are available at SEC EDGAR. DilutionWatch provides real-time alerts and risk scoring on top of the raw EDGAR filings.